—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Viking Therapeutics Inc (VKTX) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for VKTX, from the same nightly bakes the boards use. Research diary readings, not advice.

Versus its index HALO Growth 100 — the name, its sleeve and the index over day, week and month

Versus its index

The name against its Closelooknet index and its own sleeve — equal-weight, nightly closes.

HALO Growth 100 · as of 2026-10-06

DayWeekMonth3 months
VKTX−3.1%−10.8%−18.6%−29.0%
Longevity & Healthspan−1.9%−3.5%−4.0%—
HALO Growth 100+0.5%+0.7%−4.9%—

Against the index: 11.5 pts behind on the week, 13.7 pts behind on the month; against its Longevity & Healthspan sleeve 14.6 pts behind on the month.

Returns from the index workers’ nightly closes; equal-weight sleeves. A relative reading from the research diary, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
How it trades on rate days beta 0.55 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How VKTX has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.55 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Viking Therapeutics Inc moved 0.55% on average · correlation 0.08 · higher than 57% of US names
  • Beta, last 3 months 1.42 more rate-sensitive lately than over the year
  • On the 10 worst bond days −2.75% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −11.76% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against HALO Growth 100 · Longevity & Healthspan · 8 names with week and year-to-date

Peer group

HALO Growth 100 · Longevity & Healthspan

GLP-1 leaders, gene-editing platforms, diagnostics-at-scale, biopharma compounders. Demographics writes the demand curve.

Compared against VKTX on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Viking Therapeutics Inc

VKTX in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Viking Therapeutics is a clinical-stage biopharmaceutical company developing treatments for metabolic and endocrine disorders. Its lead programme is an oral thyroid hormone receptor beta agonist being tested against liver disease, alongside a selective androgen receptor modulator for post-fracture recovery and a dual GLP-1 agonist in early-stage trials. It is based in San Diego and has no approved product bringing in sales yet.
Where it sits in the stack
Viking has no seat in our AI build-out index; it sits instead in the HALO Growth 100, our growth index outside the megacaps, within the Longevity & Healthspan sleeve, where demand tracks demographics rather than data-centre spend.
Who it is priced against
Closelooknet's peer group places it with GLP-1 leaders, gene-editing platforms, diagnostics-at-scale and biopharma compounders — names such as Eli Lilly, Novo Nordisk, Regeneron, Vertex, Amgen, Zealand Pharma, Illumina and Natera; Pfizer is the wider comparison the market draws in weight-loss and metabolic drugs.
Why Closelooknet tracks it
It is a HALO Growth 100 constituent and carries a Closelooknet score, where the balance-sheet module reads strongest and the quality module weakest; the diary has not yet quoted it in an edition.
What the diary watches
The diary watches how the GLP-1 dual agonist and the liver-disease candidate progress through trials, since either readout would move a company with no product revenue yet.

Viking Therapeutics Inc (VKTX) trades on US exchanges. Constituent of HALO Growth 100.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 2 analyst actions on the wire · latest: price target by Truist, 2026-09-23

The Street on this name

Analyst actions and the latest print for VKTX from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Truist — target 87 from 83 Target raised to $87 from $83 (+129.1% to spot) 2026-09-23
  • Price target Oppenheimer — target 120 from 100 Target raised to $120 from $100 (+211.2% to spot) 2026-09-22

2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst wire → · Earnings wire →

FAQ · from the current data · as of 2026-10-07

Quick answers

What is Viking Therapeutics Inc (VKTX)?

Viking Therapeutics Inc trades as VKTX on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is VKTX in a Closelooknet index?

Yes — Viking Therapeutics Inc is a constituent of HALO Growth 100, as of 2026-10-07.

Where does VKTX trade against its moving averages?

Resizing — 32.1% off its high: 32.1% below its 52-week high, under its 200-day — a deeper resizing of the trend, not a shallow dip. As of 2026-10-05 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How is VKTX doing against its Closelooknet index?

Over the past month Viking Therapeutics Inc is −18.6% against −4.9% for the HALO Growth 100 — 13.7 points behind its index, as of 2026-10-06. Its Longevity & Healthspan sleeve is −4.0% over the same month. The “Versus its index” table on this page carries the day, the week and the month for the name, its sleeve and the index.

How does Viking Therapeutics Inc compare with its peers?

Against its peer group (HALO Growth 100 · Longevity & Healthspan), Viking Therapeutics Inc (VKTX) sits 32.1% below its 52-week high, 11.9% below its 50-day average; Eli Lilly and Company (LLY) is 11.6% below, Regeneron Pharmaceuticals Inc (REGN) is 15.5% below, Amgen Inc (AMGN) is 9.9% below. Put any of them next to VKTX in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Viking Therapeutics Inc trade when bond yields rise?

Over the past year Viking Therapeutics Inc had a beta of 0.55 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 57% of US names. On the 10 sessions in which long bonds fell most it moved −2.75% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Viking Therapeutics Inc do?

Viking Therapeutics is a clinical-stage biopharmaceutical company developing treatments for metabolic and endocrine disorders. Its lead programme is an oral thyroid hormone receptor beta agonist being tested against liver disease, alongside a selective androgen receptor modulator for post-fracture recovery and a dual GLP-1 agonist in early-stage trials. It is based in San Diego and has no approved product bringing in sales yet. Closelooknet's peer group places it with GLP-1 leaders, gene-editing platforms, diagnostics-at-scale and biopharma compounders — names such as Eli Lilly, Novo Nordisk, Regeneron, Vertex, Amgen, Zealand Pharma, Illumina and Natera; Pfizer is the wider comparison the market draws in weight-loss and metabolic drugs.

Where does Viking Therapeutics Inc sit in the AI build-out?

Viking has no seat in our AI build-out index; it sits instead in the HALO Growth 100, our growth index outside the megacaps, within the Longevity & Healthspan sleeve, where demand tracks demographics rather than data-centre spend. It is a HALO Growth 100 constituent and carries a Closelooknet score, where the balance-sheet module reads strongest and the quality module weakest; the diary has not yet quoted it in an edition.

What has Wall Street done on Viking Therapeutics Inc recently?

The most recent analyst action on Viking Therapeutics Inc on the Closelooknet wire is a price target by Truist on 2026-09-23 (target 87 from 83). 2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for VKTX, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

same Closelooknet index seat first, then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.